IN2012DN00754A - - Google Patents
Download PDFInfo
- Publication number
- IN2012DN00754A IN2012DN00754A IN754DEN2012A IN2012DN00754A IN 2012DN00754 A IN2012DN00754 A IN 2012DN00754A IN 754DEN2012 A IN754DEN2012 A IN 754DEN2012A IN 2012DN00754 A IN2012DN00754 A IN 2012DN00754A
- Authority
- IN
- India
- Prior art keywords
- compounds
- antagonists
- lpa
- medicaments
- diseases
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 abstract 3
- 239000005557 antagonist Substances 0.000 abstract 2
- 230000001419 dependent effect Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
- C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
- C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D261/14—Nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6527—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having nitrogen and oxygen atoms as the only ring hetero atoms
- C07F9/653—Five-membered rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Gastroenterology & Hepatology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pyridine Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US23128209P | 2009-08-04 | 2009-08-04 | |
| PCT/US2010/044284 WO2011017350A2 (en) | 2009-08-04 | 2010-08-03 | Compounds as lysophosphatidic acid receptor antagonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2012DN00754A true IN2012DN00754A (OSRAM) | 2015-06-19 |
Family
ID=43544907
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN754DEN2012 IN2012DN00754A (OSRAM) | 2009-08-04 | 2010-08-03 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US8592402B2 (OSRAM) |
| EP (1) | EP2462128B1 (OSRAM) |
| JP (1) | JP2013501064A (OSRAM) |
| CN (1) | CN102574822A (OSRAM) |
| IN (1) | IN2012DN00754A (OSRAM) |
| WO (1) | WO2011017350A2 (OSRAM) |
Families Citing this family (68)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010068775A2 (en) | 2008-12-11 | 2010-06-17 | Amira Pharmaceuticals, Inc. | Alkyne antagonists of lysophosphatidic acid receptors |
| GB2466121B (en) | 2008-12-15 | 2010-12-08 | Amira Pharmaceuticals Inc | Antagonists of lysophosphatidic acid receptors |
| GB2470833B (en) | 2009-06-03 | 2011-06-01 | Amira Pharmaceuticals Inc | Polycyclic antagonists of lysophosphatidic acid receptors |
| JP2013501064A (ja) | 2009-08-04 | 2013-01-10 | アミラ ファーマシューティカルス，インコーポレーテッド | リゾホスファチジン酸受容体アンタゴニストとしての化合物 |
| GB2474120B (en) | 2009-10-01 | 2011-12-21 | Amira Pharmaceuticals Inc | Compounds as Lysophosphatidic acid receptor antagonists |
| GB2474748B (en) | 2009-10-01 | 2011-10-12 | Amira Pharmaceuticals Inc | Polycyclic compounds as lysophosphatidic acid receptor antagonists |
| JP2014508111A (ja) | 2010-12-07 | 2014-04-03 | アミラ ファーマシューティカルス，インコーポレーテッド | リゾフォスファチジン酸受容体アンタゴニスト、その線維症の治療における使用 |
| EP2694496A1 (en) | 2011-04-05 | 2014-02-12 | Amira Pharmaceuticals, Inc. | 3- or 5 - bi phenyl - 4 - ylisoxazole - based compounds useful for the treatment of fibrosis, pain, cancer and respiratory, allergic, nervous system or cardiovascular disorders |
| WO2012138648A1 (en) * | 2011-04-06 | 2012-10-11 | Irm Llc | Compositions and methods for modulating lpa receptors |
| ES2609003T3 (es) * | 2011-08-08 | 2017-04-18 | Merck Patent Gmbh | Carboxamidas de n-(bencimimazol-2-il) -ciclopropano como antagonistas de ácido lisofosfatídico |
| AU2012296662A1 (en) * | 2011-08-15 | 2014-03-27 | Intermune, Inc. | Lysophosphatidic acid receptor antagonists |
| CN103987858A (zh) | 2011-11-22 | 2014-08-13 | 英特芒尼公司 | 诊断和治疗特发性肺纤维化的方法 |
| JP6258928B2 (ja) | 2012-06-13 | 2018-01-10 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | 新規ジアザスピロシクロアルカンおよびアザスピロシクロアルカン |
| CN104411690A (zh) * | 2012-06-20 | 2015-03-11 | 霍夫曼-拉罗奇有限公司 | 作为lpar拮抗剂的取代的吡唑化合物 |
| CN104703985A (zh) * | 2012-08-09 | 2015-06-10 | 神经孔疗法股份有限公司 | 作为pi3-激酶信号通路调节剂的芳基和杂芳基取代的苯衍生物 |
| DK2900669T3 (da) | 2012-09-25 | 2019-11-04 | Hoffmann La Roche | Hexahydropyrrolo[3,4-C]pyrrolderivater og relaterede forbindelser som autotaxin (ATX)-inhibitorer og som inhibitorer af lysophosphatidsyre (LPA)-produktion til behandling af f.eks. nyresygdomme |
| CA2896701C (en) | 2012-12-28 | 2020-10-06 | Ube Industries, Ltd. | Halogen-substituted heterocyclic compound |
| TW201437200A (zh) * | 2013-01-15 | 2014-10-01 | Intermune Inc | 溶血磷脂酸受體拮抗劑 |
| AR095079A1 (es) * | 2013-03-12 | 2015-09-16 | Hoffmann La Roche | Derivados de octahidro-pirrolo[3,4-c]-pirrol y piridina-fenilo |
| CA2906931C (en) * | 2013-03-15 | 2023-03-14 | Epigen Biosciences, Inc. | Heterocyclic compounds useful in the treatment of disease |
| EA038294B1 (ru) * | 2013-05-24 | 2021-08-05 | Эпиджен Байосайенсиз, Инк. | Гетероциклические соединения, применимые в лечении заболеваний |
| GB201314926D0 (en) * | 2013-08-20 | 2013-10-02 | Takeda Pharmaceutical | Novel Compounds |
| CA2923523A1 (en) | 2013-11-26 | 2015-06-04 | F. Hoffmann-La Roche Ag | New octahydro-cyclobuta [1,2-c;3,4-c']dipyrrol-2-yl |
| UA118582C2 (uk) | 2014-03-26 | 2019-02-11 | Ф. Хоффманн-Ля Рош Аг | Біциклічні сполуки як інгібітори продукції аутотаксину (atx) і лізофосфатидилової кислоти (lpa) |
| AU2015238541B2 (en) | 2014-03-26 | 2019-09-19 | F. Hoffmann-La Roche Ag | Condensed [1,4]diazepine compounds as autotaxin (ATX) and lysophosphatidic acid (LPA) production inhibitors |
| AP2016009496A0 (en) | 2014-04-04 | 2016-10-31 | X-Rx Inc | Substituted spirocydic inhibitors of autotaxin |
| EP3134079A4 (en) * | 2014-04-23 | 2017-12-20 | X-RX Discovery, Inc. | Substituted n-(2-(amino)-2-oxoethyl)benzamide inhibitors of autotaxin and their preparation and use in the treatment of lpa-dependent or lpa-mediated diseases |
| MX370408B (es) | 2014-06-27 | 2019-12-11 | Ube Industries | Sal de compuesto heterociclico sustituido con halogeno. |
| WO2016046782A1 (en) * | 2014-09-26 | 2016-03-31 | Glenmark Pharmaceuticals S.A. | Imidazole biaryl compounds as s-nitrosoglutathione reductase inhibitors |
| MA41898A (fr) | 2015-04-10 | 2018-02-13 | Hoffmann La Roche | Dérivés de quinazolinone bicyclique |
| SI3288379T1 (sl) | 2015-05-01 | 2022-06-30 | Onl Therapeutics, Inc. | Peptidne sestave in načini uporabe |
| EP3302465A1 (en) | 2015-06-05 | 2018-04-11 | Vertex Pharmaceuticals Incorporated | Triazoles for the treatment of demyelinating diseases |
| CA2992889A1 (en) | 2015-09-04 | 2017-03-09 | F. Hoffmann-La Roche Ag | Phenoxymethyl derivatives |
| BR112017026682A2 (pt) | 2015-09-24 | 2018-08-14 | Hoffmann La Roche | novos compostos bicíclicos como inibidores de dupla ação de atx/ca |
| AU2016328535A1 (en) | 2015-09-24 | 2017-11-09 | F. Hoffmann-La Roche Ag | Bicyclic compounds as ATX inhibitors |
| MX2018001890A (es) | 2015-09-24 | 2018-06-20 | Hoffmann La Roche | Compuestos biciclicos como inhibidores de autotaxina (atx). |
| KR20180054634A (ko) | 2015-09-24 | 2018-05-24 | 에프. 호프만-라 로슈 아게 | 이중 오토탁신(atx)/탄산 무수화효소(ca) 억제제로서 신규한 이환형 화합물 |
| WO2018106646A1 (en) | 2016-12-06 | 2018-06-14 | Vertex Pharmaceuticals Incorporated | Aminotriazoles for the treatment of demyelinating diseases |
| WO2018106643A1 (en) | 2016-12-06 | 2018-06-14 | Vertex Pharmaceuticals Incorporated | Heterocyclic azoles for the treatment of demyelinating diseases |
| WO2018106641A1 (en) | 2016-12-06 | 2018-06-14 | Vertex Pharmaceuticals Incorporated | Pyrazoles for the treatment of demyelinating diseases |
| CN110382484B (zh) | 2017-03-16 | 2022-12-06 | 豪夫迈·罗氏有限公司 | 新的作为atx抑制剂的二环化合物 |
| SG11201908560SA (en) | 2017-03-16 | 2019-10-30 | Hoffmann La Roche | Heterocyclic compounds useful as dual atx/ca inhibitors |
| AU2018359224B2 (en) | 2017-10-30 | 2023-10-05 | Neuropore Therapies, Inc. | Substituted phenyl sulfonyl phenyl triazole thiones and uses thereof |
| ES2944304T3 (es) * | 2017-12-19 | 2023-06-20 | Bristol Myers Squibb Co | Pirazol azinas de ácido ciclohexílico como antagonistas de LPA |
| SG11202005698XA (en) | 2017-12-19 | 2020-07-29 | Bristol Myers Squibb Co | Cyclohexyl acid triazole azines as lpa antagonists |
| CN112041302B (zh) * | 2017-12-19 | 2024-11-19 | 百时美施贵宝公司 | 作为lpa拮抗剂的吡唑o-连接的氨基甲酰基环己基酸 |
| US11384067B2 (en) | 2017-12-19 | 2022-07-12 | Bristol-Myers Squibb Company | Pyrazole n-linked carbamoyl cyclohexyl acids as LPA antagonists |
| KR102756639B1 (ko) * | 2017-12-19 | 2025-01-16 | 브리스톨-마이어스 스큅 컴퍼니 | Lpa 길항제로서의 시클로헥실 산 이속사졸 아졸 |
| EP3727589B1 (en) | 2017-12-19 | 2022-06-29 | Bristol-Myers Squibb Company | Cyclohexyl acid pyrazole azoles as lpa antagonists |
| JP7526096B2 (ja) * | 2017-12-19 | 2024-07-31 | ブリストル－マイヤーズ スクイブ カンパニー | Ｌｐａアンタゴニストとしてのシクロヘキシル酸イソキサゾールアジン |
| WO2019126099A1 (en) * | 2017-12-19 | 2019-06-27 | Bristol-Myers Squibb Company | Isoxazole n-linked carbamoyl cyclohexyl acids as lpa antagonists |
| EA202091505A1 (ru) * | 2017-12-19 | 2020-09-22 | Бристол-Маерс Сквибб Компани | Триазолазолы циклогексильной кислоты в качестве антагонистов lpa |
| EP3710438B1 (en) | 2017-12-19 | 2021-10-20 | Bristol-Myers Squibb Company | Triazole n-linked carbamoyl cyclohexyl acids as lpa antagonists |
| KR102697358B1 (ko) * | 2017-12-19 | 2024-08-20 | 브리스톨-마이어스 스큅 컴퍼니 | Lpa 길항제로서의 이속사졸 o-연결된 카르바모일 시클로헥실 산 |
| WO2020060915A1 (en) | 2018-09-18 | 2020-03-26 | Bristol-Myers Squibb Company | Cyclopentyl acids as lpa antagonists |
| EP3853232B1 (en) | 2018-09-18 | 2023-03-01 | Bristol-Myers Squibb Company | Oxabicyclo acids as lpa antagonists |
| US12466804B2 (en) | 2019-06-18 | 2025-11-11 | Bristol-Myers Squibb Company | Cyclobutyl carboxylic acids as LPA antagonists |
| CN114599640A (zh) | 2019-06-18 | 2022-06-07 | 百时美施贵宝公司 | 作为lpa拮抗剂的异噁唑羧酸 |
| US12435057B2 (en) | 2019-06-18 | 2025-10-07 | Bristol-Myers Squibb Company | Triazole carboxylic acids as LPA antagonists |
| KR20220039718A (ko) * | 2019-07-30 | 2022-03-29 | 다이쇼 세이야꾸 가부시끼가이샤 | Lpa1 수용체를 길항하는 우레아 화합물 |
| US11548871B2 (en) | 2019-11-15 | 2023-01-10 | Gilead Sciences, Inc. | Triazole carbamate pyridyl sulfonamides as LPA receptor antagonists and uses thereof |
| TWI838626B (zh) | 2020-06-03 | 2024-04-11 | 美商基利科學股份有限公司 | Lpa受體拮抗劑及其用途 |
| EP4161936A1 (en) | 2020-06-03 | 2023-04-12 | Gilead Sciences, Inc. | Lpa receptor antagonists and uses thereof |
| WO2022006470A1 (en) | 2020-07-01 | 2022-01-06 | Vanderbilt University | Methods of treatment for a kidney disease |
| CN115989220A (zh) * | 2020-07-16 | 2023-04-18 | 奇斯药制品公司 | 作为lpa受体抑制剂的酰氨基环己烷酸衍生物 |
| TWI818538B (zh) | 2021-05-11 | 2023-10-11 | 美商基利科學股份有限公司 | Ｌｐａ受體拮抗劑及其用途 |
| US12503454B2 (en) | 2021-05-13 | 2025-12-23 | Gilead Sciences, Inc. | LPA receptor antagonists and uses thereof |
| US11939318B2 (en) | 2021-12-08 | 2024-03-26 | Gilead Sciences, Inc. | LPA receptor antagonists and uses thereof |
Family Cites Families (68)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4229447A (en) | 1979-06-04 | 1980-10-21 | American Home Products Corporation | Intraoral methods of using benzodiazepines |
| US4476116A (en) | 1982-12-10 | 1984-10-09 | Syntex (U.S.A.) Inc. | Polypeptides/chelating agent nasal compositions having enhanced peptide absorption |
| US5116817A (en) | 1982-12-10 | 1992-05-26 | Syntex (U.S.A.) Inc. | LHRH preparations for intranasal administration |
| US4596795A (en) | 1984-04-25 | 1986-06-24 | The United States Of America As Represented By The Secretary, Dept. Of Health & Human Services | Administration of sex hormones in the form of hydrophilic cyclodextrin derivatives |
| JPH0778017B2 (ja) | 1985-12-28 | 1995-08-23 | 住友製薬株式会社 | パルス的かつ持続放出性製剤 |
| US4755386A (en) | 1986-01-22 | 1988-07-05 | Schering Corporation | Buccal formulation |
| US5739136A (en) | 1989-10-17 | 1998-04-14 | Ellinwood, Jr.; Everett H. | Intraoral dosing method of administering medicaments |
| US5017381A (en) | 1990-05-02 | 1991-05-21 | Alza Corporation | Multi-unit pulsatile delivery system |
| US5229135A (en) | 1991-11-22 | 1993-07-20 | Prographarm Laboratories | Sustained release diltiazem formulation |
| US5612359A (en) | 1994-08-26 | 1997-03-18 | Bristol-Myers Squibb Company | Substituted biphenyl isoxazole sulfonamides |
| GB9523946D0 (en) | 1995-11-23 | 1996-01-24 | Bayer Ag | Leukotriene antagonistic benzoic acid derivatives |
| US5837284A (en) | 1995-12-04 | 1998-11-17 | Mehta; Atul M. | Delivery of multiple doses of medications |
| ATE236890T1 (de) | 1996-12-23 | 2003-04-15 | Bristol Myers Squibb Pharma Co | Sauerstoff oder schwefel enthaltende 5-gliedrige heteroaromatishe derivative als factor xa hemmer |
| JP3237608B2 (ja) | 1997-04-21 | 2001-12-10 | 住友製薬株式会社 | イソキサゾール誘導体 |
| US5840329A (en) | 1997-05-15 | 1998-11-24 | Bioadvances Llc | Pulsatile drug delivery system |
| US6391452B1 (en) | 1997-07-18 | 2002-05-21 | Bayer Corporation | Compositions for nasal drug delivery, methods of making same, and methods of removing residual solvent from pharmaceutical preparations |
| DE60003025T2 (de) | 1999-04-02 | 2004-03-18 | Bristol-Myers Squibb Pharma Co. | Arylsulfonyle als faktor xa inhibitoren |
| TWI288136B (en) | 2000-02-18 | 2007-10-11 | Kirin Brewery | Novel isoxazole and thiazole compounds and use thereof as drugs |
| WO2002000651A2 (en) | 2000-06-27 | 2002-01-03 | Bristol-Myers Squibb Pharma Company | Factor xa inhibitors |
| JP4396808B2 (ja) | 2001-02-08 | 2010-01-13 | 小野薬品工業株式会社 | Ｌｐａ受容体調節剤からなる泌尿器疾患治療剤 |
| US7521192B2 (en) | 2001-04-18 | 2009-04-21 | Rigel Pharmaceuticals, Inc. | EDG: modulators of lymphocyte activation and migration |
| DE60228732D1 (de) | 2001-07-17 | 2008-10-16 | Ono Pharmaceutical Co | Mittel zur regulierung der sekretion von pankreassaft mit einem lpa-rezeptor-regler |
| MY151199A (en) | 2001-11-02 | 2014-04-30 | Rigel Pharmaceuticals Inc | Substituted diphenyl heterocycles useful for treating hcv infection |
| AU2002367129A1 (en) | 2001-12-25 | 2003-07-15 | Ajinomoto Co., Inc. | Organ fibrosis inhibitors |
| US20050113283A1 (en) | 2002-01-18 | 2005-05-26 | David Solow-Cordero | Methods of treating conditions associated with an EDG-4 receptor |
| EP1513522A2 (en) | 2002-01-18 | 2005-03-16 | Sri International | Methods of treating conditions associated with an edg receptor |
| US20050261298A1 (en) | 2002-01-18 | 2005-11-24 | David Solow-Cordero | Methods of treating conditions associated with an Edg-7 receptor |
| US20050101518A1 (en) | 2002-01-18 | 2005-05-12 | David Solow-Cordero | Methods of treating conditions associated with an EDG-2 receptor |
| AU2003233119A1 (en) | 2002-05-08 | 2003-11-11 | Neuronova Ab | Modulation of neural stem cells with s1p or lpa receptor agonists |
| AU2003222648A1 (en) | 2002-05-13 | 2003-12-02 | Eli Lilly And Company | Multicyclic compounds for use as melanin concentrating hormone antagonists in the treatment of obesity and diabetes |
| EP1533294A4 (en) | 2002-05-28 | 2007-07-04 | Ono Pharmaceutical Co | BETA-ALANINE DERIVATIVE AND USE THEREOF |
| AU2003241834A1 (en) | 2002-06-26 | 2004-01-19 | Ono Pharmaceutical Co., Ltd. | Remedy for chronic disease |
| TW200408393A (en) | 2002-10-03 | 2004-06-01 | Ono Pharmaceutical Co | Antagonist of lysophosphatidine acid receptor |
| US20040171037A1 (en) | 2002-11-19 | 2004-09-02 | Jing Li | Amplified genes involved in cancer |
| US20040167132A1 (en) | 2003-01-16 | 2004-08-26 | Geetha Shankar | Methods of treating conditions associted with an Edg-2 receptor |
| US20040192739A1 (en) | 2003-01-16 | 2004-09-30 | David Solow-Cordero | Methods of treating conditions associated with an Edg-2 receptor |
| US20050065194A1 (en) | 2003-01-16 | 2005-03-24 | Geetha Shankar | Methods of treating conditions associated with an Edg-2 receptor |
| US7135469B2 (en) | 2003-03-18 | 2006-11-14 | Bristol Myers Squibb, Co. | Linear chain substituted monocyclic and bicyclic derivatives as factor Xa inhibitors |
| US7115642B2 (en) | 2003-05-02 | 2006-10-03 | Rigel Pharmaceuticals, Inc. | Substituted diphenyl isoxazoles, pyrazoles and oxadiazoles useful for treating HCV infection |
| US7462629B2 (en) | 2003-05-19 | 2008-12-09 | Irm Llc | Immunosuppressant compounds and compositions |
| WO2005012269A1 (ja) * | 2003-08-05 | 2005-02-10 | Ajinomoto Co., Inc. | 新規アゾール化合物 |
| JP4766384B2 (ja) | 2003-12-19 | 2011-09-07 | 小野薬品工業株式会社 | リゾホスファチジン酸受容体拮抗作用を有する化合物およびその用途 |
| DE10360369A1 (de) | 2003-12-22 | 2005-07-14 | Bayer Cropscience Ag | Amide |
| JP2006096712A (ja) | 2004-09-30 | 2006-04-13 | Senju Pharmaceut Co Ltd | Ｌｐａ受容体拮抗剤を含有する角膜知覚改善剤 |
| AR055041A1 (es) | 2005-03-23 | 2007-08-01 | Merck Frosst Canada Ltd | Tiadiazoles y oxadiazoles como inhibidores de la sintesis de leucotrienos. composiciones farmaceuticas. |
| US20080306124A1 (en) | 2005-06-08 | 2008-12-11 | Rainer Albert | Polycyclic Oxadiazoles or I Soxazoles and Their Use as Sip Receptor Ligands |
| WO2007007588A1 (ja) | 2005-07-08 | 2007-01-18 | Ono Pharmaceutical Co., Ltd. | 平面性を有する環状基を母核とする化合物 |
| AU2006279211A1 (en) | 2005-08-11 | 2007-02-15 | Merck Frosst Canada Ltd | Novel substituted 1,2,3-triazolylmethyl-benzothiophene or -indole and their use as leukotriene biosynthesis inhibitors |
| RU2008110949A (ru) | 2005-08-23 | 2009-09-27 | Айрм Ллк (Bm) | Соединения и композиции-иммуносупрессанты |
| US7405302B2 (en) | 2005-10-11 | 2008-07-29 | Amira Pharmaceuticals, Inc. | 5-lipoxygenase-activating protein (FLAP) inhibitors |
| US7977359B2 (en) | 2005-11-04 | 2011-07-12 | Amira Pharmaceuticals, Inc. | 5-lipdxygenase-activating protein (FLAP) inhibitors |
| US20070225285A1 (en) | 2005-11-04 | 2007-09-27 | Amira Pharmaceuticals, Inc. | 5-lipoxygenase-activating protein (flap) inhibitors |
| US20070219206A1 (en) | 2005-11-04 | 2007-09-20 | Amira Pharmaceuticals, Inc. | 5-lipoxygenase-activating protein (flap) inhibitors |
| CA2636043A1 (en) | 2006-01-23 | 2007-08-02 | Amira Pharmaceuticals, Inc. | Tricyclic inhibitors of 5-lipoxygenase |
| CA2643670A1 (en) | 2006-02-27 | 2007-08-30 | Sterix Limited | Diaryl compounds as non-steroidal inhibitors of 17-beta hydroxysteroid dehydrogenase and/or steroid sulphatase for the treatment of oestrogen-related diseases such as hormone dependent breast cancer |
| WO2007139946A2 (en) | 2006-05-25 | 2007-12-06 | University Of Tennessee Research Foundation | Gpcr ligands identified by computational modeling |
| WO2008024979A2 (en) | 2006-08-24 | 2008-02-28 | The Scripps Research Institute | Methods utilizing cell-signaling lysophospholipids |
| US20080051372A1 (en) | 2006-08-24 | 2008-02-28 | The Scripps Research Institute | Methods utilizing cell-signaling lysophospholipids |
| US20100143381A1 (en) | 2007-03-12 | 2010-06-10 | Andrew Tager | Lysophosphatidic acid receptor targeting for lung disease |
| US9163091B2 (en) | 2007-05-30 | 2015-10-20 | Lpath, Inc. | Compositions and methods for binding lysophosphatidic acid |
| US20090069288A1 (en) * | 2007-07-16 | 2009-03-12 | Breinlinger Eric C | Novel therapeutic compounds |
| CA2723302C (en) | 2008-05-05 | 2013-08-20 | Sanofi-Aventis | Acylamino-substituted fused cyclopentanecarboxylic acid derivatives and their use as pharmaceuticals |
| WO2010068775A2 (en) | 2008-12-11 | 2010-06-17 | Amira Pharmaceuticals, Inc. | Alkyne antagonists of lysophosphatidic acid receptors |
| GB2466121B (en) | 2008-12-15 | 2010-12-08 | Amira Pharmaceuticals Inc | Antagonists of lysophosphatidic acid receptors |
| GB2470833B (en) | 2009-06-03 | 2011-06-01 | Amira Pharmaceuticals Inc | Polycyclic antagonists of lysophosphatidic acid receptors |
| JP2013501064A (ja) | 2009-08-04 | 2013-01-10 | アミラ ファーマシューティカルス，インコーポレーテッド | リゾホスファチジン酸受容体アンタゴニストとしての化合物 |
| GB2474748B (en) | 2009-10-01 | 2011-10-12 | Amira Pharmaceuticals Inc | Polycyclic compounds as lysophosphatidic acid receptor antagonists |
| GB2474120B (en) | 2009-10-01 | 2011-12-21 | Amira Pharmaceuticals Inc | Compounds as Lysophosphatidic acid receptor antagonists |
-
2010
- 2010-08-03 JP JP2012523709A patent/JP2013501064A/ja active Pending
- 2010-08-03 CN CN2010800429638A patent/CN102574822A/zh active Pending
- 2010-08-03 US US13/388,502 patent/US8592402B2/en active Active
- 2010-08-03 EP EP10807045.9A patent/EP2462128B1/en not_active Not-in-force
- 2010-08-03 IN IN754DEN2012 patent/IN2012DN00754A/en unknown
- 2010-08-03 WO PCT/US2010/044284 patent/WO2011017350A2/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| US8592402B2 (en) | 2013-11-26 |
| WO2011017350A3 (en) | 2011-06-30 |
| EP2462128A4 (en) | 2012-10-03 |
| JP2013501064A (ja) | 2013-01-10 |
| WO2011017350A2 (en) | 2011-02-10 |
| EP2462128B1 (en) | 2016-09-21 |
| CN102574822A (zh) | 2012-07-11 |
| EP2462128A2 (en) | 2012-06-13 |
| US20120196839A1 (en) | 2012-08-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IN2012DN02177A (OSRAM) | ||
| IN2012DN02702A (OSRAM) | ||
| IN2012DN00754A (OSRAM) | ||
| PH12013501136A1 (en) | Lysophosphatidic acid receptor antagonists and uses thereof | |
| MY163055A (en) | Polycyclic antagonists of lysophosphatidic acid receptors | |
| WO2010077883A3 (en) | Antagonists of lysophosphatidic acid receptors | |
| PH12020550450A1 (en) | Certain chemical entities, compositions and methods | |
| PH12015501737B1 (en) | Androgen receptor modulators and uses thereof | |
| PH12013500481A1 (en) | Estrogen receptor modulators and uses thereof | |
| PH12012502419A1 (en) | Estrogen receptor modulators and uses thereof | |
| WO2010068775A3 (en) | Alkyne antagonists of lysophosphatidic acid receptors | |
| PH12014501351B1 (en) | Fluorinated estrogen receptor modulators and uses thereof | |
| PH12014502095A1 (en) | Estrogen receptor modulators and uses thereof | |
| WO2012024620A3 (en) | Autotaxin inhibitors and uses thereof | |
| UA98839C2 (en) | N,n-disubstituted aminoalkylbiphenyl antagonists of prostaglandin d2 receptors | |
| IN2012DN02471A (OSRAM) | ||
| TN2010000463A1 (en) | Compositions and methods for preparing and using same |